deltatrials
Completed PHASE4 INTERVENTIONAL 3-arm NCT03033745

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency

Sponsor: CSL Behring

Conditions Primary Immunodeficiency
Interventions IgPro20
Updated 19 times since 2017 Last updated: Mar 16, 2020 Started: Feb 1, 2017 Primary completion: Dec 14, 2018 Completion: Dec 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Primary Immunodeficiency, this trial is completed. The trial is conducted by CSL Behring and has accumulated 19 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Dec 2018 · 5 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Feb 2020 · 12 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE4

▶ Show 14 earlier versions

  1. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE4

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE4

  3. Feb 2020 — Apr 2020 [monthly]

    Completed PHASE4

  4. Feb 2019 — Feb 2020 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  5. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  6. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE4

  7. Jul 2018 — Dec 2018 [monthly]

    Recruiting PHASE4

  8. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE4

  9. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

  10. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE4

  11. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE4

  12. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE4

  13. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE4

  14. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CSL Behring
Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Birmingham, United States , Charlotte, United States , Durham, United States , Great Neck, United States , Litchfield Park, United States , Milwaukee, United States , Montreal, Canada , New York, United States , Ottawa, Canada and 2 more locations